3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Carcinoma, Non-Small-Cell Lung
2
Squamous Cell Carcinoma of Head and Neck
1
Solitary Fibrous Tumors
1
Sarcoma
1
Ovarian Neoplasms
1
Lung Neoplasms
1
Liposarcoma
1
Histiocytoma, Malignant Fibrous
1
Fallopian Tube Neoplasms
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Dermatofibrosarcoma
1
Colorectal Neoplasms
1
Interventions
Cisplatin
26
Paclitaxel
21
pembrolizumab
15
Radiotherapy
13
Carboplatin
13
tislelizumab
12
Fluorouracil
12
Drug Therapy
11
Irinotecan
9
toripalimab
8
Esophagectomy
8
Oxaliplatin
6
Nivolumab
6
Capecitabine
6
Neoadjuvant Therapy
5
Leucovorin
5
Docetaxel
5
lenvatinib
4
camrelizumab
4
Taxes
4
Radiation
4
Levoleucovorin
4
Immune Checkpoint Inhibitors
4
Albumin-Bound Paclitaxel
4
130-nm albumin-bound paclitaxel
4
spartalizumab
3
sintilimab
3
apatinib
3
Itraconazole
3
Injections
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Squamous Cell Carcinoma
×
Histamine H2 Antagonists
×
1 year
×
Clear all
NCT05319730
2026-05-26
MK-3475-06B
Merck Sharp & Dohme LLC
Phase 1/2
Recruiting
230 enrolled